>900,000-Mr Cryptosporidium sporozoite glycoprotein (GP900) that is a prominent antigen recognized by protective hyperimmune bovine colostral immunoglobulin. Three of six murine anticryptosporidial monoclonal antibodies reacted with GP900, indicating that the molecule is highly immunogenic in mice as well as in cows. GP900 is Triton X-100 soluble and N glycosylated. Western blotting of the N-deglycosylated protein, detected with antibodies eluted from recombinant clones expressing a partial GP900 fusion protein, suggested that the polypeptide backbone of the glycoprotein has an Mr of < 190,000. GP900 is encoded by a single-copy gene that resides on the largest Cryptosporidium chromosome.
Cryptosporidium parvum is a coccidian parasite of the gastrointestinal tract that causes a clinical syndrome of diarrhea for which there is currently no effective treatment. Infection of immunocompetent individuals is usually selflimited (36) . However, infection of immunocompromised patients, especially those with AIDS, is often persistent and may produce life-threatening malabsorption and dehydration (6, 24, 27) . Infection is acquired by the oral ingestion of oocysts which rupture in the upper intestine and release sporozoites that invade the microvillus border of epithelial cells. The intracellular parasites multiply asexually, producing merozoites which emerge from the host cell and infect adjacent cells. Some merozoites differentiate sexually into gametes, and fusion of gametes produces new oocysts that are shed into the intestinal lumen. Many oocysts are excreted with the feces, but some rupture in the intestinal lumen, releasing invasive sporozoites and producing a cycle of autoinfection. Autoinfection may contribute to the heavy parasite burdens and the persistent infections that occur in immunocompromised individuals.
Although naturally acquired immunity to C. parvum appears to involve both the cellular and humoral arms of the immune response (6, 18, 24, 27, 35) , studies with animals and humans indicate that antibody alone can prevent new infection, can ameliorate established infection, and may be efficacious in the treatment of immunocompromised individuals with cryptosporidiosis (1, 3, 4, 8, 10, 19, 20, 25, 26, 30, (32) (33) (34) . Preincubation of sporozoites with monoclonal antibodies (MAbs) to sporozoite antigens reduced sporozoite infectivity 80 to 100% in a mouse model of C. parvum infection (25, 26) , and the passive transfer of one of these antisporozoite MAbs to animals with established infection reduced the numbers of infected intestinal epithelial cells (3) . Hyperimmune bovine colostrum (HBC), prepared by immunizing cows with oocysts, also neutralized sporozoite infectivity in animals and reduced clinical symptoms and oocyst excretion in some patients with AIDS and cryptosporidiosis (8, 10, 19, 20, (32) (33) (34) . The immunoglobulin fraction of HBC (HBC Ig) appeared to contain the neutralizing activity (9, 29) . These studies indicate that intraluminal administration of antibodies to C. parvum may be an effective treatment for cryptosporidiosis in immunocompromised individuals. The most likely targets for these antibodies are the extracellular, intraluminal life cycle stages of the parasite, the sporozoites and merozoites.
Important steps in the development of antibody-mediated immunotherapy for cryptosporidiosis are the identification and characterization of specific protective antigens. In addition, molecular cloning and in vitro expression of protective antigens by recombinant DNA techniques would facilitate the preparation of large amounts of polyclonal antibody and would yield a more uniform product than immunizations with oocysts. We report here the identification and biochemical characterization of GP900, a >900,000-Mr Cryptosporidium glycoprotein and the initial molecular biological characterization of its gene. GP900 is a very prominent sporozoite antigen recognized by protective HBC Ig.
CRYPTOSPORIDIUM SPOROZOITE ANTIGEN

MATERIALS AND METHODS
Parasites. Cryptosporidium sp. oocysts isolated from San Francisco General Hospital patients with AIDS were used in the production of polyclonal antibodies and MAbs and for electrophoretic karyotype analysis. C. parvum, AUCP-1 isolate (Byron Blagburn, Auburn University, Auburn, Ala.), was propagated in Holstein calves and was used for immunoprecipitations, Western blots (immunoblots), indirect immunofluorescent-antibody (EFA) studies, and genomic Southern and electrophoretic karyotype analyses. Qocysts were isolated from feces as previously described (11) . A calf isolate of C.
panvum was used to prepare HBC Ig at ImmuCell Corp.
Preparation of polyclonal antibodies, MAbs, and REA. Polyclonal antibodies to oocyst and sporozoite proteins were produced as previously described (21) . MAbs were prepared by using a similar immunization regimen followed by a final intravenous booster dose with the supernatant from sonicated oocysts given through the tail vein 3 days before fusion. Spleens were removed from each mouse for fusion with cells of the mouse myeloma cell line X63.Ag8.653, a non-Ig secretor (13) , by a technique previously described (7 (11) were probed with MAbs for 1 h in a humidified chamber, washed with phosphate-buffered saline, pH 7.4, and incubated with affinity-purified goat anti-mouse IgG-IgA-IgM antibody conjugated with fluorescein isothiocyanate (Zymed). Slides were counterstained with Evans blue, coverslipped, and observed and photographed with a Nikon Optiphot microscope equipped for immunofluorescence with fluorescein (21) .
Western blot of oocyst/sporozoite proteins. Sporozoites were excysted as previously described (11), solubilized in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) reducing sample buffer and fractionated by SDS-5% PAGE (17) . Oocysts containing sporozoites were suspended in a cocktail of protease inhibitors, lysed by five freeze-thaw cycles (21) , and fractionated directly, after extraction in an equal volume of 2% Triton X-100, or after extraction of the Triton X-100-insoluble pellet in equal volumes of the protease inhibitor cocktail and 4% SDS (12) . To ensure efficient transfer, proteins were electroblotted to nitrocellulose membranes (31) for at least 7 h at 700 mA at 8°C. Western blots were probed with MAbs, S34 REA (21), or HBC Ig. Antibodies were detected by using 1"I-protein G Immunoprecipitations. One percent Triton X-100 parasite protein extracts and 2% SDS extracts of the remaining 1% Triton X-100-insoluble proteins were immunoprecipitated as previously described for malaria parasites (12) . Immune complexes were collected with protein A-agarose beads, separated by reducing SDS-5% PAGE, Western blotted, and detected as described above.
Deglycosylation of N-linked carbohydrate moieties. Prior to gel electrophoresis and Western blotting, a parasite lysate, prepared in the presence of protease inhibitors, was incubated overnight at 37°C with N-glycosidase F (Boehringer Mannheim) according to the manufacturer's instructions. To control for proteolysis during incubation, the parasite lysate was also incubated under identical conditions in the absence of N-glycosidase F.
Genomic Southern and molecular karyotypic analyses. Restriction of the lambda gtll clone S34 with EcoRI resulted in the excision of a 1.2-kb foreign DNA insert (data not shown).
Genomic Southern analysis and [32P]dATP labeling of the 1.2-kb S34 DNA insert cloned into pGem was carried out as previously described (23) . After hybridization, membranes were washed with 0.1x SSPE (lx SSPE is 0.15 M NaCl, 10 mM NaPO4, and 1 mM EDTA [pH 7.7])-0.25% Sarkosyl at 65°C and autoradiographed. Figure 6A is the digitized reproduction of the autoradiogram obtained by scanning with a Hewlett-Packard flatbed scanning densitometer in the reflectance mode. Southern molecular karyotypic analysis was performed after contour-clamped homogeneous electric field fractionation of Cryptosporidium chromosomes of both human and animal origin, transfer of the fractionated chromosomes to nylon membranes, and hybridization with labeled pGem S34 (14) .
RESULTS
Ig from protective HBC reacts with a >900000-Mr antigen of C. parvum sporozoites. We used HBC (lot 40529) which (Fig. 3) . Thus, MAb 1OC6 recognized an epitope common to sporozoites and merozoites. The >900,000-Mr protein is N glycosylated and Triton X-100 soluble. To determine whether the >900,000-Mr antigen is a glycoprotein, we performed deglycosylation experiments with N-glycosidase F, which removes N-linked carbohydrates, and then Western blotting and probing with an antibody to the protein portion of the >900,000-Mr protein.
The polypeptide-reactive antibody, REA, was affinity purified from HBC Ig (Fig. 4) or polyclonal antisporozoite mouse serum (Fig. 5) on a lambda gtll genomic library clone (S34) expressing part of a >900,000-Mr antigen. S34 REA recognized the >900,000-Mr antigen that was immunoprecipitated by MAb 1OC6 (Fig. 4) and, as previously reported (21) that is dependent on intact N glycosylation, and (iii) the Mr of the N-deglycosylated protein(s) is < 190,000. We have called the >900,000-Mr glycoprotein GP900. Inmmunoprecipitation of Triton X-100-soluble oocyst/sporozoite proteins (Fig. 5, lane 6 ) and the SDS extract of the Triton X-100-insoluble pellet (Fig. 5, lane 7) indicated that almost all of GP900 is Triton X-100 soluble. 6 and 7) . The Mr of the large glycoprotein was estimated by comparing its migration with those of other large proteins of known Mrs. GP900 migrated more rapidly than titin, a 2.5-MDa protein (16) , and more slowly than nebulin, a 900-kDa protein (28) , indicating that its Mr is greater than 900,000.
tive efficacy of antibody to GP900 would be facilitated by its molecular cloning and in vitro expression using recombinant DNA techniques. As an initial step toward this goal, we isolated the 1.2-kb S34 insert which encodes a portion of GP900. Genomic Southern analysis showed that the S34 insert hybridized with single BstEII, ApaI, BclI, ClaI, and SspI fragments of approximately 9.0, >23, >23, 6, and 4 kb, respectively, and with two restriction fragments generated by BanII (Fig. 6A) . These results indicated that GP900 was encoded by a single-copy gene. Molecular karyotypic analysis revealed that the gene is located on the largest detected Cryptosporidium chromosome, a chromosome of approximately 1,400 kb, and is present in both bovine and human isolates (Fig. 6B) .
DISCUSSION
A plausible approach to the treatment of cryptosporidiosis in immunocompromised individuals is passive immunotherapy with antibodies directed against C. parvum sporozoites and/or merozoites in the lumen of the gastrointestinal tract. To identify potentially protective antigens, we performed a Western blot analysis of oocyst/sporozoite antigens with partially purified Ig from an HBC preparation that reduced infection and inhibited parasite development in vivo. We report here the identification and biochemical characterization of GP900 and the initial molecular biological investigation of its gene. The abundance and immunogenicity of GP900 suggested that it might be a protective antigen and led us to initiate this biochemical and molecular characterization. 4) and bovine (AUCP-1) (lanes 2 and 5) origin separated by contour-clamped homogeneous electric field fractionation. Lanes 3 and 6 contain Saccharomyces cerevisiae chromosomal DNA size standards. Lanes 1 to 3 are stained with ethidium bromide. Lanes 4 to 6 are the corresponding lanes after transfer to a nylon membrane, hybridization with pGem S34, and autoradiography. The S34 gene was present on a chromosome of the same size, approximately 1,400 kb, in the karyotypes of both human and bovine C. parvum isolates. In addition, all of the separated chromosomes of these two isolates appeared to be of the same size.
Our inspection of Coomassie blue-stained gels after electrophoretic separation of sporozoite proteins suggested that GP900 was abundant. GP900 reacted more strongly with HBC Ig than did any other Triton X-100-soluble protein. GP900 was the target of three of six sporozoite-reactive murine MAbs from one fusion, suggesting that GP900 is highly immunogenic in mice as well as in cows. Previous investigations of HBC-reactive antigens did not identify GP900, perhaps because of its very large size and its migration near the top of SDS gels containing higher percentages of acrylamide (29, 35) . We performed SDS-PAGE of sporozoite proteins in gels containing 5% acrylamide, which facilitated the resolution and identification of very large proteins.
Our deglycosylation experiments with N-glycosidase F indicated that the polypeptide backbone of GP900 had an Mr of <190,000, suggesting that a very large fraction of the native protein was carbohydrate. GP900-reactive polyclonal antibodies (S34 REA) detected multiple proteins with Mrs of <190,000 after N deglycosylation of GP900, whereas the specific MAbs detected comigrating N-deglycosylated molecules only when the more sensitive "2I-protein A method and prolonged autoradiography were used. These proteins appear to represent stepwise N deglycosylation of a protein that is either heavily glycosylated or glycosylated with very large complex mucopolysaccharides. Alternatively, they may represent partially N-deglycosylated glycoproteins of different sizes which migrate together in the compressed high-Mr region of the gel. The latter explanation seems less likely as GP900 is the product of a single-copy gene. The markedly reduced reactivity of all three MAbs with N-deglycosylated GP900 suggests that the N-linked carbohydrates are the targets of the MAbs and that they elicit an intense immunologic response. GP900 was detected in C. parvum isolated from calves by MAbs raised against C parvum isolated from humans. A DNA probe derived from a library constructed from a bovine isolate hybridized under stringent conditions with genomic DNA of a human Cryptosporidium isolate. Taken together, these data indicate that the protein and its gene are present in isolates from both sources and that there is significant conservation at the amino acid and DNA sequence levels.
Both the anti-GP900 MAbs and REA reacted by immunofluorescence with acetone-fixed sporozoites but not with unfixed sporozoites, suggesting that most of GP900 is intracellular. The immunofluorescence was localized over the anterior region of the sporozoite. No reactivity was seen with excysted oocysts. The immunofluorescence studies confirmed that GP900 is a sporozoite protein, but the function of GP900 in the biology of C. parvum has not been determined. Recent experiments, however, suggest that GP900 and a smaller molecule, which is a product of or cross-reacts with GP900, can be surface labeled with 1"I (7a) .
We also observed that the anti-GP900 MAbs reacted with intracellular C. parvum merozoites, with a circumferential distribution around the entire merozoite. This result indicates that GP900 or an immunologically cross-reactive molecule is expressed by merozoites as well as sporozoites, but the different immunofluorescence patterns with MAb 10C6 for merozoites and sporozoites are unexplained. Other shared epitopes of C. parvum sporozoites and merozoites have been described previously (4, 30) . Immunotherapy with antibodies against antigens common to both sporozoites and merozoites might be more effective than with antibodies that react with only one or the other of these two life cycle stages.
We conclude that GP900 is an abundant and immunogenic glycoprotein of C. parvum sporozoites and possibly of merozoites and that it is a potential target for passive immunotherapy against cryptosporidiosis. We are attempting to determine whether monospecific antibodies to recombinant or purified GP900 are effective against C. parvum infection in vivo and in vitro and to identify the biological function of GP900.
